From the CEO's Desk
Swaroop Vakkalanka, PhD
Founder & CEO
Rhizen Pharma was founded with a vision to discover and develop novel onco-therapeutics designed to improve the quality of life of patients and drive transformative outcomes.
Rhizen is deeply committed to fulfilling this vision to address the immense unmet need that exists for patients living with cancer.
At Rhizen we practice
Fostering a culture of cutting-edge innovation as has been evidenced by our pivotal leadership in the “Targeted Drugs for Oncology & Inflammation” space through our focus on platforms that are fortified with foundational and expansive assets
Staying focused on the patient care with a relentless drive; tracking the evolution of relevant biology and explore remedies for challenges thrown
Creative collaboration and partnerships across global markets and research institutes
Purposeful communication to ensure the team’s focus on imaginative outcomes As we head into 2025 with aspirations to grow as full-fledged development company,
We firmly believe we are poised to make tangible difference to cancer care and to potentially bring to market innovative medicines fostering productive collaborations. This is at the core of our philosophy and shapes the values at our company.
Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors
Rhizen Pharmaceuticals AG announced today that it is presenting data from an ongoing Phase 2 trial of Tenalisib in locally advanced or metastatic breast cancer and data from a concluded dose escalation phase of RP12146 at ESMO 2022, Paris from Sept 9-13, 2022
Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation From an Ongoing Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients At ESMO Breast Cancer Meeting 2022
Rhizen Pharma reports encouraging initial results from an ongoing phase II trial to evaluate Tenalisib (RP6530; isoform-selective dual PI3K δ/γ inhibitor with additional SIK3 inhibitory activity) in patients with locally advanced or metastatic breast cancer (mBC)
Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022
Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs.
Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I/Ib Study of Its Novel PARP Inhibitor (RP12146) in Patients With Advanced Solid Tumors
Rhizen Pharma commences dosing in a phase I/Ib trial to evaluate its novel PARP inhibitor (RP12146) in patients with advanced cancers.
Rhizen Pharma commences dosing in a phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/γ inhibitor with additional SIK3 activity) in patients with locally advanced or metastatic breast cancer
Hyperactivation of the PI3K pathway in breast cancer is implicated in malignant transformation, cancer progression, and resistance to endocrine therapy. Salt Inducible Kinase- 3 (SIK3) is highly expressed in breast cancer and elevated SIK3 expressions are shown to contribute to tumorigenesis. Tenalisib (RP6530), a highly selective PI3K δ/γ and SIK3 inhibitor has been evaluated in > 150 patients with haematological malignancies and demonstrated encouraging activity in T-cell lymphoma with a differentiated safety profile. Tenalisib has a major metabolite (IN0385) which shows potent SIK3 inhibition. Preclinical studies in breast cancer cell lines have demonstrated that Tenalisib potentiated the activity of taxol and doxorubicin. The aim of this phase II study was to investigate the efficacy and safety of single-agent tenalisib in patients (pts) with HR+ HER2- locally advanced or metastatic breast cancer (MBC)
Hyperactivation of PI3K pathway in breast cancer is implicated in malignant transformation, progression, and resistance to endocrine therapy. Salt Inducible Kinase- 3 (SIK3) is highly expressed in breast cancer and elevated SIK3 is shown to contribute to tumorigenesis. Tenalisib (RP6530), a PI3K δ/γ and SIK3 inhibitor has been evaluated in patients with haematological malignancies and demonstrated encouraging activity in T-cell lymphoma. Tenalisib’s major metabolite (IN0385) shows potent SIK3 inhibition Preclinical studies in breast cancer cell lines have demonstrated that tenalisib potentiates activity of taxol and doxorubicin
RP12146 is a next generation potent, small molecule selective PARP 1/2 inhibitor with a wide therapeutic window with no evidence of dose limiting toxicities reported for the first-generation inhibitors.
RP7214 is a novel and potent DHODH inhibitor that inhibited DHODH activity in enzyme and PHA induced HWB/PBMC proliferation with IC50 and EC50 values of 7.8 & 2.5/0.60 nM respectively. Herein, we describe the efficacy of RP7214 as a single agent and in combination with standard of care drugs in preclinical models of AML
The Rhizen Blog